A research team in Japan has developed an innovative system that can accurately detect genetic mutations in brain tumors within just 25 minutes. Genetic mutations are crucial markers for diagnosis of ...
BEIJING, April 19, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in ...
A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic ...
Leonora Balaj, PhD, an investigator in the department of Neurosurgery at Massachusetts General Hospital and an assistant professor of Neurosurgery at Harvard Medical School, is co-senior author of a ...
A research team in Japan has developed an innovative system that can accurately detect genetic mutations in the brain tumor within just 25 minutes. Genetic mutations are crucial markers for diagnosis ...
A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 ...
Combining cell-free RNA (cfRNA) with cell-free total nucleic acid (cfTNA) as a new paradigm for liquid biopsy. Comparison of S2HG, R2HG, tRS, and rRS in the serum of IDH1/2-mutant ICCA vs. GM pts. SD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback